SCHEMBL25259166

SCHEMBL25259166

O=[N+]([O-])c1cc(Cl)ccc1-n1ncnn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.54
▸ L3MBTL1 Q9Y468 5/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ MAPT P10636 6/20 0.46
▸ LMNA P02545 5/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ POLB P06746 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ TSHR P16473 1/20 0.45
▸ PKM P14618 1/20 0.44
▸ VCAM1 P19320 1/20 0.43
▸ HTT P42858 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ PDE4B Q07343 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ PDE7A Q13946 1/20 0.40
▸ PDE7B Q9NP56 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758132 0.75 MAPT (0.65) MAPK1L3MBTL1ALDH1A1MAPTKMT2A
SCHEMBL7445704 0.75 MAPT (0.65) MAPK1L3MBTL1ALDH1A1MAPTKMT2A
SCHEMBL29957683 0.75 ALDH1A1 (0.52) MAPK1L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL23466439 0.75 ALDH1A1 (0.52) MAPK1L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL30462906 0.72 ALDH1A1 (0.45) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL25263301 0.72 CYP19A1 (0.39) L3MBTL1LMNAHTTNPSR1
SCHEMBL25306043 0.72 ALDH1A1 (0.45) MAPK1ALDH1A1LMNAKMT2AMEN1
SCHEMBL25842528 0.72 CYP19A1 (0.39) L3MBTL1ALDH1A1LMNAKMT2AMEN1
SCHEMBL25321511 0.72 MAPK1 (0.52) MAPK1L3MBTL1ALDH1A1MAPTLMNA
SCHEMBL11824811 0.71 MAPK1 (0.59) MAPK1L3MBTL1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 — — US disclosed
EP-4463462-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2024-11-20 — — EP disclosed
CN-118715231-A Complement factor inhibitors and uses thereof 安尼艾克松股份有限公司 2024-09-27 — — CN disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 — — US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 — — US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 — — US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 — — WO disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAPK1 2160/4885L3MBTL1 4785/4885ALDH1A1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback